Results 51 to 60 of about 381,135 (230)

Synthesis of heparosan oligosaccharides by Pasteurella multocida PmHS2 single-action transferases [PDF]

open access: yes, 2012
Pasteurella multocida heparosan synthase PmHS2 is a dual action glycosyltransferase that catalyzes the polymerization of heparosan polymers in a non-processive manner.
Boeriu, C.G.   +3 more
core   +2 more sources

Intravitreal low molecular weight heparin in PVR surgery.

open access: yesIndian Journal of Ophthalmology, 2003
Purpose: To evaluate the efficacy of low molecular weight heparin (LMWH) in prevention of postoperative fibrin formation following vitreoretinal surgery with proliferative vitreoretinopathy (PVR).
Kumar Atul   +2 more
doaj  

Bioequivalence of a biosimilar enoxaparin (Cloti‐Xa™) and its innovator (Clexane®): A single‐dose, randomized, double‐blind, two‐period, two‐treatment, two‐sequence, crossover, balanced study in healthy human subjects

open access: yesPharmacology Research & Perspectives, 2022
Currently, several biosimilars of low‐molecular‐weight heparins (LMWHs) with differing potencies are being developed and marketed globally. Thus, it is important that the potency of each biosimilar LMWH be compared with its innovator's molecule.
Sumit Saxena   +3 more
doaj   +1 more source

Safety of Needle Electromyography in Critically Ill Patients [PDF]

open access: yes, 2020
Introduction: To evaluate the safety of needle electromyography (EMG) in critically ill intensive care unit (ICU) patients who are on anticoagulants and have comorbidities that increase the risk of bleeding and infections.
Bollu, Pradeep   +5 more
core   +2 more sources

THROMBOTECT – a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescents

open access: yesHaematologica, 2018
Thromboembolism is a serious complication of induction therapy for childhood acute lymphoblastic leukemia. We prospectively compared the efficacy and safety of antithrombotic interventions in the consecutive leukemia trials ALL-BFM 2000 and AIEOP-BFM ALL
J. Greiner   +18 more
semanticscholar   +1 more source

IS THE INCIDENCE TREND OF HEPARIN-INDUCED THROMBOCYTOPENIA DECREASED BY THE INCREASED USE OF LOW-MOLECULAR-WEIGHT-HEPARIN?

open access: yesMediterranean Journal of Hematology and Infectious Diseases, 2015
Background: The increasing trend of using low-molecular-weight-heparin (LMWH) versus unfractionated heparin (UFH) in hospitalized adult patients is raising concerns about the incidence of heparin-induced thrombocytopenia (HIT).
Fahad Al-Eidan
doaj   +1 more source

pH-Sensitive Chitosan–Heparin Nanoparticles for Effective Delivery of Genetic Drugs into Epithelial Cells [PDF]

open access: yes, 2019
Chitosan has been extensively studied as a genetic drug delivery platform. However, its efficiency is limited by the strength of DNA and RNA binding.
Korzhikov-Vlakh, Viktor   +7 more
core   +1 more source

Beneficial non-anticoagulant mechanisms underlying heparin treatment of COVID-19 patients

open access: yesEBioMedicine, 2020
Coronavirus disease-2019 (COVID-19) is associated with severe inflammation in mainly the lung, and kidney. Reports suggest a beneficial effect of the use of heparin/low molecular weight heparin (LMWH) on mortality in COVID-19.
Baranca Buijsers   +4 more
doaj   +1 more source

The ISFET based heparin sensor with a monolayer of protamine as affinity ligand [PDF]

open access: yes, 1995
The ion-step measuring method was used to determine absolute heparin concentrations in PBS and blood plasma with a Ta2O5 ISFET on to which a monolayer of protamine had been immobilized. Heparin is a highly negatively charged polysaccharide, which is used
Bergveld, P.   +2 more
core   +2 more sources

The anti-factor Xa range for low molecular weight heparin thromboprophylaxis

open access: yesHematology Reports, 2015
Low molecular weight heparins (LMWHs) are now the mainstay option in the prevention and treatment of venous thromboembolism. In some patients receiving therapeutic doses of LMWH, activity can be measured by quantifying the presence of Anti-factor Xa ...
Matthew Y. Wei, Salena M. Ward
doaj   +1 more source

Home - About - Disclaimer - Privacy